Qiagen this week announced that it has launched the Therascreen IDH1/2 RGQ kit in Europe and other certain markets after the test received CE marking.

The test is based on Qiagen's proprietary biomarkers for IDH1 and IDH2 gene mutations, and enables detection of 12 such mutations using real-time PCR. It is designed to enable physicians to better diagnose and assess the prognoses of patients with gliomas, or tumors of the brain and spinal cord.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.